Wednesday, March 12, 2008 9:37:31 AM
Does this news have any implications for Proellex? Wouldn't Daiichi be better off buying our drug?
Posted by: DewDiligence
In reply to: None Date:3/12/2008 6:28:00 AM
Post #of 60265
FDA Rejects Daiichi Sankyo Drug for Uterine Bleeding
[This is yet another case where the FDA contravened the recommendation from an advisory panel.]
http://www.reuters.com/article/marketsNews/idINT24684720080312
>>
Wed Mar 12, 2008 3:48am EDT
TOKYO, March 12 (Reuters) - U.S. regulators have rejected Daiichi Sankyo Co Ltd's injectable anaemia drug Injectafer for the broad treatment of uterine bleeding and in a surprise move also knocked it back for a narrower use.
The Japanese drug maker, which licensed rights to the drug from Swiss healthcare provider Galenica, said it had received a "non-approvable" letter from the U.S. Food and Drug Administration.
An advisory panel to the FDA had voted in February against recommending broad use of the drug but said the benefits outweighed the risks for women who could not tolerate oral iron or had an unsatisfactory response to it.
Galenica shares soared last month after it appeared likely to receive approval for the narrower indication.
The FDA is not bound by the panel's recommendations but takes the advice into consideration.
The FDA asked for additional trials and safety data and Daiichi Sankyo said in a statement it would continue to develop the drug.
<<
Posted by: DewDiligence
In reply to: None Date:3/12/2008 6:28:00 AM
Post #of 60265
FDA Rejects Daiichi Sankyo Drug for Uterine Bleeding
[This is yet another case where the FDA contravened the recommendation from an advisory panel.]
http://www.reuters.com/article/marketsNews/idINT24684720080312
>>
Wed Mar 12, 2008 3:48am EDT
TOKYO, March 12 (Reuters) - U.S. regulators have rejected Daiichi Sankyo Co Ltd's injectable anaemia drug Injectafer for the broad treatment of uterine bleeding and in a surprise move also knocked it back for a narrower use.
The Japanese drug maker, which licensed rights to the drug from Swiss healthcare provider Galenica, said it had received a "non-approvable" letter from the U.S. Food and Drug Administration.
An advisory panel to the FDA had voted in February against recommending broad use of the drug but said the benefits outweighed the risks for women who could not tolerate oral iron or had an unsatisfactory response to it.
Galenica shares soared last month after it appeared likely to receive approval for the narrower indication.
The FDA is not bound by the panel's recommendations but takes the advice into consideration.
The FDA asked for additional trials and safety data and Daiichi Sankyo said in a statement it would continue to develop the drug.
<<
Recent RPRX News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/15/2026 08:38:40 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/14/2026 09:22:49 PM
- Form 13F-NT - Quarterly report filed by institutional managers, Notice • Edgar (US Regulatory) • 05/14/2026 06:29:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/08/2026 09:14:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/08/2026 09:12:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/08/2026 09:10:50 PM
- Royalty Pharma to present at upcoming investor conferences • GlobeNewswire Inc. • 05/07/2026 08:15:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/06/2026 01:04:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 11:31:54 AM
- Royalty Pharma reports first quarter 2026 results • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/30/2026 09:54:06 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/28/2026 09:00:16 PM
- Royalty Pharma Launches Global Translational Prize to Recognize Breakthrough Scientific Innovation • GlobeNewswire Inc. • 04/21/2026 05:00:00 PM
- Royalty Pharma Declares Second Quarter 2026 Dividend • GlobeNewswire Inc. • 04/17/2026 12:30:00 PM
- Royalty Pharma to Announce First Quarter 2026 Financial Results on May 6, 2026 • GlobeNewswire Inc. • 04/15/2026 08:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/13/2026 01:53:04 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/10/2026 08:11:03 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 08:10:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 09:58:57 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/01/2026 08:55:58 PM
- Royalty Pharma signs $500M co-development agreement with J&J • IH Market News • 03/30/2026 12:28:19 PM
- Royalty Pharma Announces R&D Funding Collaboration for Chronic Immune-Mediated Diseases • GlobeNewswire Inc. • 03/30/2026 11:15:00 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/23/2026 08:43:18 PM
